Clinical Trial Update: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation [Phase 3]

View source ↗

Summary

A completed Phase 3 study evaluated transitioning schizophrenia patients stabilized on paliperidone palmitate 1-month to the 3-month formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
• Invega Trinza (paliperidone palmitate)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED